Author: Editor

Neha Vapiwala, MD Professor of Radiation Oncology at the Hospital of the University of PennsylvaniaDepartment: Radiation Oncology, Penn Medicine speaks about the JAMA Oncology -  Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades. Link to Abstract:https://pubmed.ncbi.nlm.nih.gov/34882189/A summary -Significance:It’s unclear how the historical exclusion of women and racial and ethnic minorities from medical school and, as a result, oncologic subspecialties, has influenced faculty diversity in oncology departments over time. Oncologic faculty diversity is a critical strategy for improving cancer care and addressing health inequities in an increasingly diverse US cancer community.Goals:To describe…

Dr. Stephen Malamud is the regional director of medical oncology at Nuvance Health. He is a board-certified and fellowship-trained physician who specializes in medical oncology for breast cancer. As an active clinical researcher, Dr. Malamud has been involved in trials that resulted in the approval of new cancer treatments. He is a nationally and internationally sought-after speaker. Dr. Malamud came from Mount Sinai Beth Israel Medical Center in New York before joining Nuvance Health. In this video he speaks about – An update of the targeted therapies for Her-2 and TNBC cancers with emphasis on the Destiny Trial (Enhertu) in…

Dr. Stephen Malamud is the regional director of medical oncology at Nuvance Health. He is a board-certified and fellowship-trained physician who specializes in medical oncology for breast cancer. As an active clinical researcher, Dr. Malamud has been involved in trials that resulted in the approval of new cancer treatments. He is a nationally and internationally sought-after speaker. Dr. Malamud came from Mount Sinai Beth Israel Medical Center in New York before joining Nuvance Health. In this video he speaks about – An update of the targeted therapies for Her-2 and TNBC cancers with emphasis on the Destiny Trial (Enhertu) in…

Saad Z. Usmani, MD MBA FACP, Chief, Myeloma Service at Memorial Sloan Kettering Cancer Center speaks about New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma.Link to Article:https://www.prnewswire.com/news-releases/new-data-from-majestec-1-study-show-continued-deep-and-durable-responses-of-teclistamab-bcmaxcd3-bispecific-antibody-in-treatment-of-heavily-pretreated-patients-with-multiple-myeloma-301443200.htmlThe MajesTEC-1 study of teclistamab, an off-the-shelf T-cell experimental redirecting bispecific antibody, is being evaluated for the treatment of patients with relapsed or refractory multiple myeloma. An overall response rate (ORR) of 62 percent was observed in heavily pretreated patients (n=150) across the Phase 1 and 2 studies who had received at least three prior lines of…

Saad Z. Usmani, MD MBA FACP, Chief, Myeloma Service at Memorial Sloan Kettering Cancer Center speaks about New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma.Link to Article:https://www.prnewswire.com/news-releases/new-data-from-majestec-1-study-show-continued-deep-and-durable-responses-of-teclistamab-bcmaxcd3-bispecific-antibody-in-treatment-of-heavily-pretreated-patients-with-multiple-myeloma-301443200.htmlThe MajesTEC-1 study of teclistamab, an off-the-shelf T-cell experimental redirecting bispecific antibody, is being evaluated for the treatment of patients with relapsed or refractory multiple myeloma. An overall response rate (ORR) of 62 percent was observed in heavily pretreated patients (n=150) across the Phase 1 and 2 studies who had received at least three prior lines of…

Colin C. Pritchard, MD, Professor, Co-Director, Genetics, and Solid Tumors Laboratory, Precision Diagnostics Platform Head, Brotman Baty Institute For Precision Medicine, UW Medicine Laboratory Medicine & Pathology. In this video speaks about Inherited TP53 Variants and Risk of Prostate Cancer.Link to Article:https://newsroom.uw.edu/news/inherited-mutation-linked-aggressive-prostate-cancerLink to Study:https://www.sciencedirect.com/science/article/pii/S0302283821021394?via%3DihubAbstract:Backstory:Autosomal dominant multicancer predisposition, including Li-Fraumeni syndrome, is caused by inherited germline TP53 pathogenic and possibly pathogenic mutations (gTP53) (LFS). However, there is no documented link between gTP53 and prostate cancer.Goal:To see if gTP53 plays a role in prostate cancer predisposition.Participants, setting, and design:The incidence of prostate cancer in a cohort of LFS males and the prevalence…

Colin C. Pritchard, MD, Professor, Co-Director, Genetics, and Solid Tumors Laboratory, Precision Diagnostics Platform Head, Brotman Baty Institute For Precision Medicine, UW Medicine Laboratory Medicine & Pathology. In this video speaks about Inherited TP53 Variants and Risk of Prostate Cancer.Link to Article:https://newsroom.uw.edu/news/inherited-mutation-linked-aggressive-prostate-cancerLink to Study:https://www.sciencedirect.com/science/article/pii/S0302283821021394?via%3DihubAbstract:Backstory:Autosomal dominant multicancer predisposition, including Li-Fraumeni syndrome, is caused by inherited germline TP53 pathogenic and possibly pathogenic mutations (gTP53) (LFS). However, there is no documented link between gTP53 and prostate cancer.Goal:To see if gTP53 plays a role in prostate cancer predisposition.Participants, setting, and design:The incidence of prostate cancer in a cohort of LFS males and the prevalence…

Jason Luke, MD, FACP, Director, Cancer Immunotherapeutics Center at UPMC Hillman Cancer Center speaks about FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection.Link to Article:https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-as-adjuvant-treatment-for-adult-and-pediatric-%e2%89%a512-years-of-age-patients-with-stage-iib-or-iic-melanoma-following-complete-resectio/The US Food and Drug Administration (FDA) has approved Merck’s anti-PD-1 medication, KEYTRUDA, for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following full resection. The FDA also increased the indication for KEYTRUDA as an adjuvant treatment for stage III melanoma after full resection to include pediatric patients…

Jason Luke, MD, FACP, Director, Cancer Immunotherapeutics Center at UPMC Hillman Cancer Center speaks about FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection.Link to Article:https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-as-adjuvant-treatment-for-adult-and-pediatric-%e2%89%a512-years-of-age-patients-with-stage-iib-or-iic-melanoma-following-complete-resectio/The US Food and Drug Administration (FDA) has approved Merck’s anti-PD-1 medication, KEYTRUDA, for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following full resection. The FDA also increased the indication for KEYTRUDA as an adjuvant treatment for stage III melanoma after full resection to include pediatric patients…

Jacob Laubach, MD, MPP from the Dana-Farber Cancer Institute speaks about the ASH 2021 Abstract – 79 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper149024.htmlIntroduction:DARA is approved for NDMM and MM that have been previously treated. DARA plus RVd (D-RVd) improved the rate of stringent complete response (sCR) by the end of post-ASCT consolidation versus RVd (42.4 percent vs 32.0 percent, 1-sided P=0.068) in the primary analysis of the phase 2 GRIFFIN trial (NCT02874742) in autologous stem cell transplant…

Jacob Laubach, MD, MPP from the Dana-Farber Cancer Institute speaks about the ASH 2021 Abstract – 79 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper149024.htmlIntroduction:DARA is approved for NDMM and MM that have been previously treated. DARA plus RVd (D-RVd) improved the rate of stringent complete response (sCR) by the end of post-ASCT consolidation versus RVd (42.4 percent vs 32.0 percent, 1-sided P=0.068) in the primary analysis of the phase 2 GRIFFIN trial (NCT02874742) in autologous stem cell transplant…

Javier Cortés, MD, Ph.D., Founder, and director of the International Breast Cancer Center (IBCC), in Madrid, Spain. Dr. Javier Cortés Castán is a leading oncologist of international renown in the research and treatment of breast cancer. Speaks about the SABCS 2021 Abstract – GS1-02 Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4

Javier Cortés, MD, Ph.D., Founder, and director of the International Breast Cancer Center (IBCC), in Madrid, Spain. Dr. Javier Cortés Castán is a leading oncologist of international renown in the research and treatment of breast cancer. Speaks about the SABCS 2021 Abstract – GS1-02 Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4

Ruben A. Mesa, MD, FACP from Mays Cancer Center, UT Health San Antonio Cancer Center speaks about the ASH 2021 Abstract – 1490 INDEPENDENCE: A Phase 3 Study of Efficacy and Safety of Luspatercept Versus Placebo in Patients with Myeloproliferative Neoplasm-Associated Myelofibrosis on JAK2 Inhibitor Therapy and Requiring Red Blood Cell Transfusions.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145717.htmlBackground:Ineffective erythropoiesis, faulty bone marrow (BM) function, and fibrosis, and a higher likelihood of progression to acute myeloid leukemia are all symptoms of myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) (AML). Anemia is present in up to 60% of patients (pts) at the time of diagnosis, and all pts…

Ruben A. Mesa, MD, FACP from Mays Cancer Center, UT Health San Antonio Cancer Center speaks about the ASH 2021 Abstract – 1490 INDEPENDENCE: A Phase 3 Study of Efficacy and Safety of Luspatercept Versus Placebo in Patients with Myeloproliferative Neoplasm-Associated Myelofibrosis on JAK2 Inhibitor Therapy and Requiring Red Blood Cell Transfusions.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145717.htmlBackground:Ineffective erythropoiesis, faulty bone marrow (BM) function, and fibrosis, and a higher likelihood of progression to acute myeloid leukemia are all symptoms of myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) (AML). Anemia is present in up to 60% of patients (pts) at the time of diagnosis, and all pts…

Sara Tolaney, MD from Dana Farber Cancer Institute speaks about the SABCS 2021 Presentation – Heterogeneity in treatment outcomes for HER2+ breast cancer – clinical management strategies.

Sara Tolaney, MD from Dana Farber Cancer Institute speaks about the SABCS 2021 Presentation – Heterogeneity in treatment outcomes for HER2+ breast cancer – clinical management strategies.

Courtney D. DiNardo, MD, MSCE, is a clinical researcher who focuses on prognostication and customized treatments for myeloid malignancies patients at The University of Texas Anderson Cancer Center. Speaks about the ASH 2021 Abstract – 1243 Outcomes for Patients with Late-Stage Mutant-IDH2 (mIDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147593.htmlBackground:For older patients (pts) with R/R AML, the prognosis is poor, especially if numerous lines of AML treatment (Tx) have failed. After each Tx failure, achieving a response becomes increasingly difficult, and many patients are unable…

Courtney D. DiNardo, MD, MSCE, is a clinical researcher who focuses on prognostication and customized treatments for myeloid malignancies patients at The University of Texas Anderson Cancer Center. Speaks about the ASH 2021 Abstract – 1243 Outcomes for Patients with Late-Stage Mutant-IDH2 (mIDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147593.htmlBackground:For older patients (pts) with R/R AML, the prognosis is poor, especially if numerous lines of AML treatment (Tx) have failed. After each Tx failure, achieving a response becomes increasingly difficult, and many patients are unable…

Geoffrey B. Pelz, MD, Thoracic Surgical Oncology, Hackensack Meridian Health speaks about the New GPS-Like Technology to Detect & Help Treat Lung Cancer at Hackensack University Medical Center.Link to Article:http://www.amboyguardian.com/2021/10/08/new-gps-like-technology-to-detect-help-treat-lung-cancer-at-hackensack-university-medical-centerAs we approach World Lung Day on September 25, 2021, a day dedicated to raising awareness about the importance of lung health, lung cancer remains the leading cause of cancer death for both men and women in the United States, owing to its difficulty in early detection.Certain lung lesions may be dangerous or impossible to identify with typical biopsy techniques. As a result, lung cancer can progress before it is discovered.While…

Geoffrey B. Pelz, MD, Thoracic Surgical Oncology, Hackensack Meridian Health speaks about the New GPS-Like Technology to Detect & Help Treat Lung Cancer at Hackensack University Medical Center.Link to Article:http://www.amboyguardian.com/2021/10/08/new-gps-like-technology-to-detect-help-treat-lung-cancer-at-hackensack-university-medical-centerAs we approach World Lung Day on September 25, 2021, a day dedicated to raising awareness about the importance of lung health, lung cancer remains the leading cause of cancer death for both men and women in the United States, owing to its difficulty in early detection.Certain lung lesions may be dangerous or impossible to identify with typical biopsy techniques. As a result, lung cancer can progress before it is discovered.While…

Maureen M. Achebe, MD, MPH, Associate Physician, Brigham and Women’s Hospital, Assistant Professor of Medicine, Harvard Medical School, Associate Director, Brigham and Women’s Hospital Infusion Center speaks about the ASH 2021 Abstract – 3114 Long-Term Safety and Efficacy of Voxelotor for Patients with Sickle Cell Disease: Results from an Open-Label Extension of the Phase 3 HOPE Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper153582.htmlBackground:Sickle cell disease (SCD) is a lifelong inherited blood illness caused by a mutation in the hemoglobin (Hb) subunit gene, which results in the development of sickle hemoglobin (HbS). Hemolysis, chronic anemia, and vaso-occlusive crises are all caused by HbS polymerization, which…

Maureen M. Achebe, MD, MPH, Associate Physician, Brigham and Women’s Hospital, Assistant Professor of Medicine, Harvard Medical School, Associate Director, Brigham and Women’s Hospital Infusion Center speaks about the ASH 2021 Abstract – 3114 Long-Term Safety and Efficacy of Voxelotor for Patients with Sickle Cell Disease: Results from an Open-Label Extension of the Phase 3 HOPE Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper153582.htmlBackground:Sickle cell disease (SCD) is a lifelong inherited blood illness caused by a mutation in the hemoglobin (Hb) subunit gene, which results in the development of sickle hemoglobin (HbS). Hemolysis, chronic anemia, and vaso-occlusive crises are all caused by HbS polymerization, which…

Sara A. Hurvitz, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA speaks about the SABCS 2021 Abstract – GS3-01 Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4

Sara A. Hurvitz, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA speaks about the SABCS 2021 Abstract – GS3-01 Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4

Marwan Fakih, MD, The Judy & Bernard Briskin Distinguished Director of Clinical Research; Professor, Department of Medical Oncology & Therapeutics Research; Associate Director for Clinical Research, Comprehensive Cancer Center; Medical Director, Judy & Bernard Briskin Center for Clinical Research; Co-director, Gastrointestinal Cancer Program at City of Hope. Speaks about Sotorasib for previously treated colorectal cancers with KRAS p.G12C mutation (CodeBreaK100): an interim analysis of a single-arm, Phase 2 trial.Link to Article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00605-7/fulltextBackstory:In the CodeBreaK100 phase 1 trial, sotorasib, a selective, irreversible KRASG12C protein inhibitor, showed monotherapy clinical activity in KRASG12C-mutated solid tumors, including colorectal cancer. In phase 2 of the trial,…

Marwan Fakih, MD, The Judy & Bernard Briskin Distinguished Director of Clinical Research; Professor, Department of Medical Oncology & Therapeutics Research; Associate Director for Clinical Research, Comprehensive Cancer Center; Medical Director, Judy & Bernard Briskin Center for Clinical Research; Co-director, Gastrointestinal Cancer Program at City of Hope. Speaks about Sotorasib for previously treated colorectal cancers with KRAS p.G12C mutation (CodeBreaK100): an interim analysis of a single-arm, Phase 2 trial.Link to Article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00605-7/fulltextBackstory:In the CodeBreaK100 phase 1 trial, sotorasib, a selective, irreversible KRASG12C protein inhibitor, showed monotherapy clinical activity in KRASG12C-mutated solid tumors, including colorectal cancer. In phase 2 of the trial,…

Mahmoud Elsawy, MD, MSc Assistant Professor, Division of Hematology, Dalhousie University. Medical Director of IEC Therapy Program, QEII Health Sciences Center, NS, Canada speaks about the ASH 2021 Abstract – 430 Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7). Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147598.htmlBackground:Patients with large B-cell lymphoma (LBCL) who relapse early or are unresponsive to first-line therapy have dismal outcomes. Furthermore, patients receiving second-line standard-of-care (SOC) therapy frequently report a low quality of life connected to their health (QoL; Lin…

Mahmoud Elsawy, MD, MSc Assistant Professor, Division of Hematology, Dalhousie University. Medical Director of IEC Therapy Program, QEII Health Sciences Center, NS, Canada speaks about the ASH 2021 Abstract – 430 Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147598.htmlBackground:Patients with large B-cell lymphoma (LBCL) who relapse early or are unresponsive to first-line therapy have dismal outcomes. Furthermore, patients receiving second-line standard-of-care (SOC) therapy frequently report a low quality of life connected to their health (QoL; Lin V,…

Avanish Vellanki, MBA and Robert Doebele, MD, Ph.D., Chief Executive Officer, and Co-founder, and President, Chief Scientific Officer & Co-founder of Rain Therapeutics discusses Rain Therapeutics Initiates Phase 3 MANTRA Clinical Trial of Milademetan for De-differentiated Liposarcoma and Provides Patient Update from Prior Clinical Program.Link to Article:https://www.globenewswire.com/news-release/2021/07/20/2265589/0/en/Rain-Therapeutics-Initiates-Phase-3-MANTRA-Clinical-Trial-of-Milademetan-for-De-differentiated-Liposarcoma-and-Provides-Patient-Update-from-Prior-Clinical-Program.htmlLink to Study:https://clinicaltrials.gov/ct2/show/NCT04979442Rain Therapeutics Inc., a clinical-stage company focused on precision oncology therapeutics, announced today that the first patient in the multicenter, open-label, Phase 3 registrational study (MANTRA) evaluating milademetan (RAIN-32), an oral mouse double minute 2 (MDM2) inhibitor, for the treatment of DD LPS has been randomized.The MANTRA trial is a randomized, multicenter,…

Avanish Vellanki, MBA and Robert Doebele, MD, Ph.D., Chief Executive Officer, and Co-founder, and President, Chief Scientific Officer & Co-founder of Rain Therapeutics discusses Rain Therapeutics Initiates Phase 3 MANTRA Clinical Trial of Milademetan for De-differentiated Liposarcoma and Provides Patient Update from Prior Clinical Program.Link to Article:https://www.globenewswire.com/news-release/2021/07/20/2265589/0/en/Rain-Therapeutics-Initiates-Phase-3-MANTRA-Clinical-Trial-of-Milademetan-for-De-differentiated-Liposarcoma-and-Provides-Patient-Update-from-Prior-Clinical-Program.htmlLink to Study:https://clinicaltrials.gov/ct2/show/NCT04979442Rain Therapeutics Inc., a clinical-stage company focused on precision oncology therapeutics, announced today that the first patient in the multicenter, open-label, Phase 3 registrational study (MANTRA) evaluating milademetan (RAIN-32), an oral mouse double minute 2 (MDM2) inhibitor, for the treatment of DD LPS has been randomized.The MANTRA trial is a randomized, multicenter,…

Matthew A. Ingham, MD, Assistant Professor of Medicine in the Division of Hematology and Oncology at Columbia University Vagelos College of Physicians and Surgeons speaks about Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2021 Virtual Annual Meeting.Intensity Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of proprietary immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announced today that data from…

Matthew A. Ingham, MD, Assistant Professor of Medicine in the Division of Hematology and Oncology at Columbia University Vagelos College of Physicians and Surgeons speaks about Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2021 Virtual Annual Meeting.Intensity Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of proprietary immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announced today that data from…

Terry Mamounas, MD, MPH, FACS from Orlando Health Cancer Institute speaks about the SABCS 2021 Presentation – Refining Axillary Management After Neoadjuvant Chemotherapy – What Does The Evidence Support.

Terry Mamounas, MD, MPH, FACS from Orlando Health Cancer Institute speaks about the SABCS 2021 Presentation – Refining Axillary Management After Neoadjuvant Chemotherapy – What Does The Evidence Support.

Karuppiah Kannan, Ph.D. Senior Director – Global Program Leader at Takeda Oncology speaks about the ASH 2021 Abstracts – 2488 TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data, and 2742 Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma.Link to Abstract 2488:https://ash.confex.com/ash/2021/webprogram/Paper152225.htmlBackground:TAK-981 is the first SUMOylation small-molecule inhibitor to reach clinical studies. Small ubiquitin-like modifier (SUMO) proteins are activated and covalently bound to substrate proteins during SUMOylation, a post-translational modification. Type I…

Karuppiah Kannan, Ph.D. Senior Director – Global Program Leader at Takeda Oncology speaks about the ASH 2021 Abstracts – 2488 TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data, and 2742 Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma.Link to Abstract 2488:https://ash.confex.com/ash/2021/webprogram/Paper152225.htmlBackground:TAK-981 is the first SUMOylation small-molecule inhibitor to reach clinical studies. Small ubiquitin-like modifier (SUMO) proteins are activated and covalently bound to substrate proteins during SUMOylation, a post-translational modification. Type I…

Naval Daver, MD from The University of Texas MD Anderson Cancer Center speaks about the ASH 2021 Abstract – 3426 A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145208.htmlBackground:Magrolimab (Hu5F9-G4) is an antibody that kills leukemia stem cells by encouraging tumor phagocytosis by inhibiting CD47, a macrophage immune checkpoint and “don’t eat me” signal on cancer cells. Hypomethylating drugs work along with magrolimab to increase phagocytosis by eliciting “eat me” signals on leukemic blasts. In frontline acute myeloid leukemia (AML) patients…

Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician’s Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia (ENHANCE-2 Clinical Trial) The study we are conducting here is a randomized phase 3 international study of Azacitidine Magrolimab (Hu5F9-G4), versus investigator choice therapy of either Azacitidine Venetoclax or intensive three plus seven, specifically in a molecular subset of TP53-mutated (TP53m), acute myeloid leukemia. The goal of this study is to see whether the combination treatment of Azacitidine with CD47 immune therapy Magrolimab (Hu5F9-G4) could…

Professor Jonathan Wall, Ph.D., Distinguished Professor and Director of the University of Tennessee Graduate School of Medicine’s Amyloidosis and Cancer Theranostics Program speaks about the ASH 2021 Abstract – 2952 Detection of Systemic AL Amyloidosis By 124I-p5+14 PET/CT Imaging – Providing the Complete Picture for Diagnosis.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper154327.htmlBackground:The deposition of fibrils in abdominothoracic organs, particularly the heart, liver, spleen, and kidneys, is associated with Immunoglobulin light chain-associated (AL) amyloidosis, resulting in organ failure and substantial morbidity. The fluctuating quantities of amyloid load and the varied organ presentation of amyloid make accurate and speedy diagnosis difficult. Organ biopsy and inferences based…

Craig Eagle, MD, FRACP, FRCPA from Guardant Health. In this video, he explains that the Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer. https://www.businesswire.com/news/home/20211111006023/en/Study-Shows-Guardant360%C2%AE-Liquid-Biopsy-Test-Helps-Guide-Treatment-for-Patients-with-HER2-Driven-Metastatic-Colorectal-CancerThe TRIUMPH study looked at the efficacy of pertuzumab with trastuzumab in patients with mCRC who had HER2 amplification as established by circulating tumor DNA (ctDNA) analysis or tissue genotyping. EGFR-targeting monoclonal antibodies had previously been used to treat all of the patients. Additional exploratory studies were conducted to explore if ctDNA genotyping might be used to predict treatment success, follow response, and uncover resistance mechanisms.While the efficacy of…

Professor Jonathan Wall, Ph.D., Distinguished Professor and Director of the University of Tennessee Graduate School of Medicine’s Amyloidosis and Cancer Theranostics Program speaks about the ASH 2021 Abstract – 2952 Detection of Systemic AL Amyloidosis By 124I-p5+14 PET/CT Imaging – Providing the Complete Picture for Diagnosis.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper154327.htmlBackground:The deposition of fibrils in abdominothoracic organs, particularly the heart, liver, spleen, and kidneys, is associated with Immunoglobulin light chain-associated (AL) amyloidosis, resulting in organ failure and substantial morbidity. The fluctuating quantities of amyloid load and the varied organ presentation of amyloid make accurate and speedy diagnosis difficult. Organ biopsy and inferences based…

David Spiegel, MD from Stanford University speaks about the SABCS Presentation – Hypnosis and Mindfulness.Go to the links below to download the app. https://apps.apple.com/us/app/reveri/id1547020650https://play.google.com/store/apps/details?id=com.reveri.reverihealth&hl=en_US&gl=US

David Spiegel, MD from Stanford University speaks about the SABCS Presentation – Hypnosis and Mindfulness.Go to the links below to download the app. https://apps.apple.com/us/app/reveri/id1547020650https://play.google.com/store/apps/details?id=com.reveri.reverihealth&hl=en_US&gl=US

Erika P. Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology speak about the SABCS 2021 Abstract – OT1-13-01 HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases.

Erika P. Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology speak about the SABCS 2021 Abstract – OT1-13-01 HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases.

Elisha Hughes, Ph.D., Director of Research Biostatistics at Myriad Genetics, Inc. speaks about the SABCS Abstract – P2-11-21 Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model.

Elisha Hughes, Ph.D., Director of Research Biostatistics at Myriad Genetics, Inc. speaks about the SABCS Abstract – P2-11-21 Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model.

Ajeet Gajra, MD, FACS, Chief Medical Officer at Cardinal Health Specialty Solutions speaks about the ASH 2021 Abstract – 4010 Barriers to Referral for Chimeric Antigen Receptor T Cell (CAR-T) Therapies Among U.S. Community Hematologists/Oncologists (cH/O).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148165.htmlIntroduction:Gene therapies, which include inserting, removing, or changing genetic information into a patient’s cells to treat a specific disease, are a big step forward in medicine, with the potential to cure or greatly improve the outcomes of a variety of benign and malignant hematologic disorders (American Society of Gene Therapy). For subgroups of people with spinal muscular atrophy or retinal dystrophy, gene therapies…

Ajeet Gajra, MD, FACS, Chief Medical Officer at Cardinal Health Specialty Solutions speaks about the ASH 2021 Abstract – 4010 Barriers to Referral for Chimeric Antigen Receptor T Cell (CAR-T) Therapies Among U.S. Community Hematologists/Oncologists (cH/O).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148165.htmlIntroduction:Gene therapies, which include inserting, removing, or changing genetic information into a patient’s cells to treat a specific disease, are a big step forward in medicine, with the potential to cure or greatly improve the outcomes of a variety of benign and malignant hematologic disorders (American Society of Gene Therapy). For subgroups of people with spinal muscular atrophy or retinal dystrophy, gene therapies…